Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282503 · ClinicalTrials.gov registry record · Phase 3
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Phase 3 study, sponsored by Mallinckrodt.
- Terminated
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT00282503 is a Phase 3 study that was terminated before completion, run by Mallinckrodt. The registered enrollment target is 19 participants.
The verdict
NCT00282503, a Phase 3 study, was terminated before completion, sponsored by Mallinckrodt.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of ECP treatment combined with high dose corticosteroids versus high dose corticosteroids alone, in the treatment of patients with newly diagnosed acute GvHD (Grades II to III) that developed within 100 days following an allo HPCT.
Interventions
- DRUG Methoxsalen+ECP, Methylprednisolone
- PROCEDURE Ecp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282503
The ClinicalTrials.gov registry entry for NCT00282503 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methoxsalen+ECP, Methylprednisolone is the first listed.
NCT00282503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282503 about?
NCT00282503 is a clinical study titled "Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease". The purpose of this study is to compare the safety and efficacy of ECP treatment combined with high dose corticosteroids versus high dose corticosteroids alone, in the treatment of patients with newly diagnosed acute GvHD (Grades II to III) that developed within 100 days following an allo HPCT.
What is the current status of trial NCT00282503?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2006-01.
What interventions are being tested in trial NCT00282503?
The interventions under investigation include: Methoxsalen+ECP, Methylprednisolone (DRUG), Ecp (PROCEDURE).
Who is sponsoring clinical trial NCT00282503?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.